Corvus Pharmaceuticals, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

CRVS$11.37+0.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)


· · Three Months Ended ·
· · March 31, ·
· · 2026 · · 2025 ·
Operating expenses: · · · · · ·
Research and development	$11,175	$7,453
General and administrative	3,702	2,469
Total operating expenses	14,877	9,922
Loss from operations	(14,877)	(9,922)
Interest income and other expense, net	1,784	525
Change in fair value of warrant liability	—	25,129
Loss before equity method investment	(13,093)	15,732
Loss from equity method investment	(599)	(539)
Net (loss) income	$(13,692)	$15,193
Net (loss) income per share, basic	$(0.15)	$0.21
Net loss per share, diluted	$(0.15)	$(0.13)
Shares used to compute net (loss) income per share, basic	89,996,728	72,126,496
Shares used to compute net loss per share, diluted	89,996,728	75,152,514
Other comprehensive (loss) income:
Unrealized loss on marketable securities	(334)	(23)
Cumulative foreign currency translation adjustment	104	57
Comprehensive (loss) income	$(13,922)	$15,227

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.